See more : American International Holdings Corp. (AMIH) Income Statement Analysis – Financial Results
Complete financial analysis of Assertio Holdings, Inc. (ASRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Assertio Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- BioRem Inc. (BIRMF) Income Statement Analysis – Financial Results
- Dong-Ah Geological Engineering Company Ltd. (028100.KS) Income Statement Analysis – Financial Results
- Arex Industries Limited (AREXMIS.BO) Income Statement Analysis – Financial Results
- Datasection Inc. (3905.T) Income Statement Analysis – Financial Results
- Adocia SA (ADOC.PA) Income Statement Analysis – Financial Results
Assertio Holdings, Inc. (ASRT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.assertiotx.com
About Assertio Holdings, Inc.
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 152.07M | 156.23M | 111.01M | 106.28M | 229.50M | 311.77M | 380.72M | 455.90M | 342.74M | 390.36M | 134.21M | 90.82M | 132.97M | 80.76M | 57.73M | 34.84M | 65.58M | 9.55M | 4.41M | 202.57K | 981.99K | 1.66M | 3.67M | 1.78M | 115.33K | 800.00K | 600.00K | 300.00K |
| Cost of Revenue | 27.02M | 18.75M | 15.83M | 19.87M | 9.51M | 18.48M | 72.60M | 87.41M | 67.90M | 15.15M | 7.09M | 6.04M | 5.54M | 8.10M | 5.26M | 5.77M | 2.60M | 1.60M | 908.52K | 0.00 | 0.00 | 0.00 | 0.00 | -561.76K | -643.49K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 125.05M | 137.49M | 95.18M | 86.40M | 220.00M | 293.29M | 308.13M | 368.48M | 274.84M | 375.22M | 127.11M | 84.78M | 127.43M | 72.67M | 52.47M | 29.07M | 62.99M | 7.95M | 3.50M | 202.57K | 981.99K | 1.66M | 3.67M | 2.34M | 758.82K | 1.30M | 800.00K | 300.00K |
| Gross Profit Ratio | 82.23% | 88.00% | 85.74% | 81.30% | 95.86% | 94.07% | 80.93% | 80.83% | 80.19% | 96.12% | 94.72% | 93.35% | 95.83% | 89.97% | 90.89% | 83.43% | 96.04% | 83.24% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | 131.63% | 657.97% | 162.50% | 133.33% | 100.00% |
| Research & Development | 2.84M | 0.00 | 0.00 | 4.21M | 10.11M | 8.04M | 38.62M | 32.63M | 72.44M | 7.12M | 8.07M | 15.46M | 15.19M | 20.11M | 34.30M | 27.27M | 23.34M | 26.89M | 18.37M | 21.36M | 26.90M | 24.71M | 15.46M | 7.49M | 3.73M | 2.10M | 900.00K | 400.00K |
| General & Administrative | 65.34M | 43.39M | 54.76M | 103.92M | 108.07M | 118.42M | 192.00M | 200.40M | 197.05M | 119.33M | 105.18M | 97.65M | 54.21M | 17.51M | 16.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 4.40M | 3.40M | 1.80M | 400.00K | 800.00K | 800.00K | 3.70M | 4.10M | 2.30M | 1.80M | 2.40M | 1.50M | 27.34M | 31.42M | 23.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.64M | 46.79M | 56.56M | 104.32M | 108.87M | 119.22M | 195.70M | 204.50M | 199.35M | 121.13M | 105.18M | 97.65M | 81.54M | 48.93M | 40.25M | 26.40M | 26.69M | 22.67M | 11.64M | 5.18M | 3.48M | 5.37M | 2.53M | 2.03M | 1.87M | 2.00M | 1.00M | 400.00K |
| Other Expenses | 287.10M | 32.61M | 28.11M | 24.78M | 101.77M | 101.77M | 102.75M | 106.85M | 599.00K | 10.16M | -249.00K | 481.00K | 0.00 | 0.00 | 0.00 | -7.50M | -34.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| Operating Expenses | 368.59M | 79.39M | 84.67M | 133.32M | 220.75M | 229.03M | 337.06M | 343.97M | 355.14M | 138.40M | 117.80M | 115.13M | 96.73M | 69.04M | 74.54M | 46.17M | 15.45M | 49.56M | 30.01M | 26.54M | 30.38M | 30.09M | 17.99M | 10.08M | 6.25M | 4.60M | 2.10M | 800.00K |
| Cost & Expenses | 395.61M | 98.14M | 100.50M | 153.19M | 230.25M | 247.51M | 409.66M | 431.39M | 423.04M | 153.55M | 124.89M | 121.17M | 102.28M | 77.14M | 79.80M | 51.94M | 18.04M | 51.16M | 30.92M | 26.54M | 30.38M | 30.09M | 17.99M | 9.51M | 5.61M | 4.10M | 1.90M | 800.00K |
| Interest Income | 0.00 | 7.96M | 10.22M | 15.93M | 58.39M | 1.20M | 681.00K | 485.00K | 599.00K | 215.00K | 662.00K | 520.00K | 557.00K | 839.00K | 1.05M | 2.35M | 2.27M | 2.03M | 1.45M | 489.01K | 299.14K | 101.11K | 0.00 | 222.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.38M | 7.96M | 10.22M | 15.93M | 58.39M | 68.88M | 73.55M | 83.72M | 73.44M | 23.92M | 4.49M | 39.00K | 133.00K | 572.00K | 1.00M | 555.00K | 0.00 | 0.00 | 459.74K | 928.88K | 910.42K | 732.57K | 105.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.23M | 33.41M | 29.11M | 26.38M | 102.97M | 106.43M | 105.50M | 109.38M | 83.34M | 10.16M | 4.55M | 2.02M | 420.00K | 439.00K | 808.00K | 1.15M | 865.00K | 1.38M | 1.14M | 1.70M | 1.04M | 745.14K | 610.81K | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| EBITDA | -222.45M | 72.54M | 38.78M | -3.20M | -61.12M | 213.16M | 74.05M | 133.76M | 35.94M | 252.64M | 16.68M | -27.27M | 71.68M | 4.90M | -20.21M | -13.60M | 48.40M | -40.23M | -25.37M | -24.63M | -28.35M | -27.68M | -13.71M | -7.18M | -4.85M | -2.84M | -1.00M | -500.00K |
| EBITDA Ratio | -146.28% | 58.38% | 35.88% | -23.86% | 45.74% | 53.64% | 19.57% | 28.92% | 1.06% | 63.32% | 10.15% | -31.20% | -7.00% | 5.53% | -36.42% | -67.30% | 21.07% | -421.17% | -599.99% | -12,160.55% | -2,887.38% | -2,749.98% | -373.25% | -280.87% | 6,215.39% | -412.50% | -183.33% | -166.67% |
| Operating Income | -243.54M | 57.81M | 9.42M | -46.92M | 3.20M | 43.66M | -42.18M | 24.51M | -50.40M | 236.81M | 9.32M | -30.35M | 70.70M | 3.63M | -22.07M | -17.10M | 47.54M | -41.61M | -26.51M | -26.33M | -29.40M | -28.43M | -14.32M | -7.74M | -5.49M | -3.30M | -1.30M | -500.00K |
| Operating Income Ratio | -160.15% | 37.00% | 8.49% | -44.15% | 1.39% | 14.00% | -11.08% | 5.38% | -14.71% | 60.67% | 6.94% | -33.42% | 53.17% | 4.49% | -38.23% | -49.06% | 72.49% | -435.62% | -601.81% | -13,000.40% | -2,993.76% | -1,711.27% | -389.88% | -435.66% | -4,760.78% | -412.50% | -216.67% | -166.67% |
| Total Other Income/Expenses | -10.52M | -26.65M | -9.98M | 36.64M | -28.06M | -5.68M | -61.75M | -89.01M | -72.84M | -23.71M | -4.74M | 481.00K | 424.00K | 267.00K | 49.00K | 1.79M | 39.56M | 2.03M | 2.04M | -439.87K | -5.36K | 15.56M | -3.17M | -2.19M | -12.02M | 536.86K | 0.00 | 500.00K |
| Income Before Tax | -254.05M | 31.17M | -553.00K | -45.51M | -222.48M | 37.98M | -103.92M | -64.50M | -123.24M | 213.11M | 4.58M | -29.87M | 71.12M | 3.89M | -22.02M | -15.30M | 49.81M | -39.58M | -24.47M | -26.77M | -29.40M | -12.86M | -17.49M | -9.93M | -17.51M | -2.80M | 0.00 | 0.00 |
| Income Before Tax Ratio | -167.06% | 19.95% | -0.50% | -42.83% | -96.94% | 12.18% | -27.30% | -14.15% | -35.96% | 54.59% | 3.41% | -32.89% | 53.49% | 4.82% | -38.15% | -43.92% | 75.95% | -414.36% | -555.40% | -13,217.54% | -2,994.31% | -774.33% | -476.27% | -558.82% | -15,178.98% | -350.00% | 0.00% | 0.00% |
| Income Tax Expense | 77.89M | -78.46M | 728.00K | -17.37M | -5.28M | 1.07M | -1.43M | 24.22M | -47.50M | 81.35M | -38.73M | -91.00K | 396.00K | -4.00K | -15.00K | 1.00K | 592.00K | 82.50K | -2.04M | 99.00K | 611.28K | -17.37M | 105.20K | 1.96M | 11.72M | -500.00K | -100.00K | 500.00K |
| Net Income | -331.94M | 109.63M | -1.28M | -28.14M | -217.20M | 36.91M | -102.50M | -88.72M | -75.74M | 131.76M | 43.31M | -29.78M | 70.73M | 3.90M | -22.01M | -15.30M | 49.22M | -39.66M | -24.47M | -26.87M | -30.02M | -13.49M | -17.60M | -9.70M | -17.21M | -2.80M | -1.20M | -500.00K |
| Net Income Ratio | -218.28% | 70.17% | -1.15% | -26.48% | -94.64% | 11.84% | -26.92% | -19.46% | -22.10% | 33.75% | 32.27% | -32.79% | 53.19% | 4.82% | -38.12% | -43.92% | 75.05% | -415.23% | -555.40% | -13,266.41% | -3,056.56% | -812.35% | -479.13% | -546.27% | -14,921.74% | -350.00% | -200.00% | -166.67% |
| EPS | -4.67 | 2.33 | -0.03 | -1.07 | -12.29 | 2.31 | -6.54 | -5.80 | -5.04 | 9.04 | 3.04 | -2.13 | 5.20 | 0.28 | -1.71 | -1.25 | 4.24 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| EPS Diluted | -4.67 | 2.01 | -0.03 | -1.07 | -12.29 | 2.30 | -6.54 | -5.79 | -5.04 | 8.20 | 3.00 | -2.13 | 5.04 | 0.28 | -1.71 | -1.25 | 4.20 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| Weighted Avg Shares Out | 71.03M | 47.00M | 43.17M | 26.21M | 17.68M | 15.95M | 15.68M | 15.30M | 15.03M | 14.57M | 14.18M | 13.97M | 13.64M | 13.13M | 12.88M | 12.19M | 11.49M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
| Weighted Avg Shares Out (Dil) | 71.03M | 54.67M | 43.17M | 26.21M | 17.68M | 16.05M | 15.68M | 15.32M | 15.03M | 16.58M | 14.39M | 13.97M | 14.02M | 13.34M | 12.88M | 12.19M | 11.59M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients,...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 5, 2024 in Assertio Holdings, Inc. Lawsuit - ASRT
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Assertio Holdings, Inc. Class Action: Levi & Korsinsky Reminds Assertio Holdings Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Assertio
NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) and reminds investors of the March 5, 2024 deadline...
Levi & Korsinsky Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Shareholders that lost money on Assertio Holdings, Inc. (ASRT) should contact Levi & Korsinsky about pending Class Action - ASRT
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
ASRT Investors Have Opportunity to Lead Assertio Holdings, Inc. Securities Fraud Lawsuit
LOS ANGELES , Feb. 28, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT)....
Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Shareholders that lost money on Assertio Holdings, Inc.(ASRT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Source: https://incomestatements.info
Category: Stock Reports